



US007189740B2

(12) **United States Patent**  
**Zeldis**

(10) **Patent No.:** **US 7,189,740 B2**

(45) **Date of Patent:** **\*Mar. 13, 2007**

(54) **METHODS OF USING**  
**3-(4-AMINO-OXO-1,3-DIHYDRO-ISOINDOL-**  
**2-YL)-PIPERIDINE-2,6-DIONE FOR THE**  
**TREATMENT AND MANAGEMENT OF**  
**MYELOYDYSPLASTIC SYNDROMES**

(75) Inventor: **Jerome B. Zeldis**, Princeton, NJ (US)

(73) Assignee: **Celgene Corporation**, Summit, NJ (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **10/411,649**

(22) Filed: **Apr. 11, 2003**

(65) **Prior Publication Data**

US 2004/0220144 A1 Nov. 4, 2004

**Related U.S. Application Data**

(60) Provisional application No. 60/418,468, filed on Oct. 15, 2002.

(51) **Int. Cl.**  
**A61K 31/47** (2006.01)  
**A61K 31/445** (2006.01)

(52) **U.S. Cl.** ..... **514/323**; 514/319; 514/58

(58) **Field of Classification Search** ..... 514/323,  
514/58, 319

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,536,809 A 10/1970 Appelzweig  
3,598,123 A 8/1971 Zaffaroni  
3,845,770 A 11/1974 Theeuwes et al.  
3,916,899 A 11/1975 Theeuwes et al.  
4,008,719 A 2/1977 Theeuwes et al.  
4,810,643 A 3/1989 Souza  
4,999,291 A 3/1991 Souza  
5,059,595 A 10/1991 LeGrazie  
5,073,543 A 12/1991 Marshall et al.  
5,120,548 A 6/1992 McClelland et al.  
5,134,127 A 7/1992 Stella et al.  
5,229,496 A 7/1993 Deeley et al.  
5,288,487 A 2/1994 Kawashima et al.  
5,354,556 A 10/1994 Sparks et al.  
5,385,901 A 1/1995 Kaplan et al.  
5,391,485 A 2/1995 Deeley et al.  
5,393,870 A 2/1995 Deeley et al.  
5,528,823 A 6/1996 Rudy et al.  
5,580,755 A 12/1996 Souza  
5,591,767 A 1/1997 Mohr et al.  
5,593,990 A 1/1997 D'Amato  
5,629,327 A 5/1997 D'Amato  
5,635,517 A 6/1997 Muller et al.  
5,639,476 A 6/1997 Oshlack et al.  
5,643,915 A 7/1997 Andrulis et al.

5,674,533 A 10/1997 Santus et al.  
5,698,579 A 12/1997 Muller  
5,712,291 A 1/1998 D'Amato  
5,733,566 A 3/1998 Lewis  
5,798,368 A 8/1998 Muller et al.  
5,874,448 A 2/1999 Muller et al.  
5,877,200 A 3/1999 Muller  
5,929,117 A 7/1999 Muller et al.  
5,955,476 A 9/1999 Muller et al.  
6,011,050 A 1/2000 Muller et al.  
6,071,948 A 6/2000 D'Amato  
6,228,879 B1 5/2001 Green et al.  
6,281,230 B1 8/2001 Muller et al.  
6,316,471 B1 11/2001 Muller et al.  
6,335,349 B1 1/2002 Muller et al.  
6,380,239 B1 4/2002 Muller et al.  
6,395,754 B1 5/2002 Muller et al.  
6,403,613 B1 6/2002 Man et al.  
6,420,414 B1 7/2002 D'Amato  
6,458,810 B1 \* 10/2002 Muller et al. .... 514/323  
6,469,045 B1 10/2002 D'Amato  
6,476,052 B1 11/2002 Muller et al.  
6,518,298 B2 2/2003 Green et al.  
6,673,828 B1 1/2004 Green et al.  
2001/0056114 A1 12/2001 D'Amato  
2002/0035090 A1 \* 3/2002 Zeldis et al. .... 514/58  
2002/0045643 A1 4/2002 Muller et al.  
2002/0052398 A1 5/2002 D'Amato  
2002/0054899 A1 5/2002 Zeldis  
2002/0061923 A1 5/2002 D'Amato  
2002/0161023 A1 10/2002 D'Amato  
2002/0173658 A1 11/2002 Muller et al.  
2002/0183360 A1 12/2002 Muller et al.  
2003/0028028 A1 2/2003 Man et al.

(Continued)

FOREIGN PATENT DOCUMENTS

JP 11-286455 10/1999

(Continued)

OTHER PUBLICATIONS

Strasser et al., Thalidomide treatment in multiple myeloma, ScienceDirect-Blood review, Sep. 20, 2002.\*

(Continued)

Primary Examiner—Vickie Kim  
(74) Attorney, Agent, or Firm—Jones Day

(57) **ABSTRACT**

Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

**34 Claims, No Drawings**

## U.S. PATENT DOCUMENTS

2003/0045552	A1	3/2003	Robarge et al.	
2003/0069428	A1	4/2003	Muller et al.	
2003/0096841	A1*	5/2003	Robarge et al. ....	514/323
2003/0139451	A1	7/2003	Shah et al.	
2003/0144325	A1	7/2003	Muller et al.	
2003/0181428	A1	9/2003	Green et al.	
2003/0187024	A1	10/2003	D'Amato	
2003/0191098	A1	10/2003	D'Amato	
2003/0235909	A1*	12/2003	Hariri et al. ....	435/372
2004/0029832	A1*	2/2004	Zeldis .....	514/58
2004/0067953	A1*	4/2004	Stein et al. ....	514/251
2004/0077685	A1	4/2004	Figg et al.	
2004/0077686	A1	4/2004	Dannenberg et al.	
2004/0087546	A1	5/2004	Zeldis	
2004/0091455	A1	5/2004	Zeldis	
2004/0116407	A1*	6/2004	Borisy et al. ....	514/217
2004/0122052	A1	6/2004	Muller et al.	

## FOREIGN PATENT DOCUMENTS

WO	WO 98/03502	1/1998
WO	WO 98/54170	12/1998
WO	WO 01/87306	11/2001
WO	WO 01/87307	11/2001
WO	WO01/87307 A2 *	11/2001
WO	WO 02/059106	8/2002
WO	PCT/US03/11323	9/2003
WO	WO 03/097040	11/2003
WO	WO 05/110085	11/2005

## OTHER PUBLICATIONS

US-60372348 Prov. application(Hariri et al), Filed Apr. 12, 2002.\*  
 Thomas, Deborah A., Pilot studies of Thalidomide in Acute Myelogenous . . . , Seminars in Hematology, vol. 37, No. 1, Supp Jan. 3, 2000, pp. 26-34.\*  
 Zorat et al., The clinical and biological effects of thalidomide in patients . . . British Journal of Haematology, 2001, vol. 115, pp. 881-894.\*  
 U.S. Appl. No. 60/372,348, filed Apr. 12, 2002, Hariri et al.  
 Beazley et al., 1985, "Malignant stricture at the confluence of the biliary tree: diagnosis and management," *Surg. Annu.* 17:125-41.  
 Bennett et al., 1985, "Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group," *Ann. Intern. Med.* 103(4):620-625.  
 Besa, 1992, "Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues," *Med. Clin. North Am.* 76(3):599-617.  
 Besa et al., 1990, 76(Supp. 1):133a.  
 Bowen et al., 1991, "The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin," *Br. J. Haematol.* 77(3):419-423.  
 Cartensen, 1995, *Drug Stability: Principles & Practice*, 2nd ed., Marcel Dekker, New York, NY pp. 379-380.  
 Corral et al., 1999, *Ann. Rheum. Dis.* 58(Supp. I):1107-1113.  
 Costa et al., 1998, *Blood* 92(10:suppl. 1):235b, Abstract #4007.  
 D'Amato et al., 1994 "Thalidoide is an inhibitor of angiogenesis," *PNAS USA* 91(9):4082-4085.  
 Dexter, 1989, "Haemopoietic growth factors," *Br. Med. Bull.* 45(2):337-349.  
 Dexter, 1987, "Growth factors involved in haemopoieses." *J. Cell. Sci.* 88 (Pt 1):1-6.  
 Dredge et al., 2002, "Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects," *Br. J. Cancer* 87(10):1166-1172.  
 Ehrenpreis et al., 1999, "Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial," *Gastroenterology*, 117(6):1271-1277.  
 Emens et al., 2001, "Chemotherapy: friend or foe to cancer vaccines?" *Curr. Opin. Mol. Ther.* 3(1):77-84.  
 Golde et al., 1988, "Hormones that stimulate the growth of blood cells," *Sci. Am.* 259(1):62-71.

Goldberg et al., 1990, "Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: correlation with chromosome patterns and data on patients without hematological disease," *Cancer Res.* 50(21):6876-6881.  
 Greenberg et al., 1997, "International scoring system for evaluating prognosis in myelodysplastic syndromes," *Blood* 89(6):2079-2088.  
 Gupta et al., 2001, "Adherences of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications," *Leukemia* 15:1950-1961.  
 Handman et al., 1979, "Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages," *J. Immunol.* 122(3):1134-1137.  
 Harris et al., 1999, "World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, Nov. 1997," *J. Clin. Oncol.* 17(12):3835-3849.  
 Hellstrom et al., 1990, 76(Supp. 1):279a.  
 Koch, 1985, "Thalidomide and congeners as anti-inflammatory agents," *Prog. Med. Chem.* 22:165-242.  
 Kropff, 2000, *Blood* 96(11 part 1):168a.  
 Kurland et al., 1979, "Induction of prostaglandin E synthesis in normal and neoplastic macrophages: role for colony-stimulating factor(s) distinct from effects on myeloid progenitor cell proliferation," *Proc. Natl. Acad. Sci. USA* 76(5):2326-2330.  
 Lentzsch et al., 2003, "Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo," *Leukemia* 17(1):41-44.  
 List, 2002, ASH Abstract #521.  
 Marriott et al., 2001, "Immunotherapeutic and antitumour potential of thalidomide analogues," *Expert Opin. Biol. Ther.* 1(4):675-682.  
 McCann, 1999, *Drug Topics* pp. 41-42 (Jun. 21, 1999).  
 The Merck Manual, 1999, 17<sup>th</sup> ed., pp. 953-955.  
 Metcalf, 1985, "The granulocyte-macrophage colony-stimulating factors," *Science* 229(4708):16-22.  
 Moller et al., 1997, "Inhibition of IL-12 production by thalidomide," *J. Immunol.* 159(10):5157-5161.  
 Moore, 1991, "The clinical use of colony stimulating factors," *Ann. Rev. Immunol.* 9:159-191.  
 Moore et al., 1980, "Production of lymphocyte-activating factor (Interleukin 1) by macrophages activated with colony-stimulating factors," *J. Immunol.* 125(3):1302-1305.  
 Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," *Bioorg. Med. Chem. Lett.* 9(11):1625-1630.  
 Muller et al., (1998), "Thalidomide analogs and PDE4 inhibition," *Bioorg. Med. Chem. Lett.* 8(19):2669-2674.  
 Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," *J. Med. Chem.* 39(17):3238-3240.  
 Munshi et al., 1999, *Blood* 94(10 part 1):578a.  
 Ogawa, 1989, "Hemopoietic stem cells: stochastic differentiation and humoral control of proliferation," *Environ. Health Perspect.* 80:199-207.  
 Payvandi et al., 2003, ASCO Abstract #992.  
 Penichet et al., 2001, "Antibody-cytokine fusion proteins for the therapy of cancer," *J. Immunol. Methods.* 248(1-2):91-101.  
 Physicians' Desk Reference, 2002, 56<sup>th</sup> ed. pp. 582-592, 1154-1158, 1755-1760.  
 Raza et al., 2001, "Thalidomide Produces Transfusion Independence in Long-standing Refractory Anemias of Patients with Myelodysplastic Syndromes," *Blood* 98(4):958-965.  
 Schrader et al., 1981, "The persisting (P) cell: histamine content, regulation by a T cell-derived factor, origin from a bone marrow precursor, and relationship to mast cells," *Proc. Natl. Acad. Sci. USA* 78(1):323-327.  
 Schuster et al., 1999, *Blood* 76(Supp. 1):318a.  
 Singhal et al., 1999, "Antitumor activity of thalidomide in refractory multiple myeloma," *N. Engl. J. Med.* 341(21):1565-1571.  
 Stanley et al., 1976, "Factors regulating macrophage production and growth: identity of colony-stimulating factor and macrophage growth factor," *J. Exp. Med.* 143(3):631-647.  
 Tabbara et al., 1991, "Hematopoietic growth factors," *Anticancer Res.* 11(1):81-90.

- Vadas et al., 1983, "Eosinophil activation by colony-stimulating factor in man: metabolic effects and analysis by flow cytometry," *Blood* 61(6):1232-1241.
- Vadas et al., 1983, "Activation of antibody-dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors," *J. Immunol.* 130(2):795-799.
- Vasiliauskas et al., 1999, "An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease," *Gastroenterology* 117(6):1278-1287.
- Weisbart et al., 1986, "Biosynthetic human GM-CSF modulates the number and affinity of neutrophil f-Met-Leu-Phe receptors," *J. Immunol.* 137(11):3584-3587.
- Wolff, ed., 1995, *Burger's Medicinal Chemistry and Drug Discovery*, 5<sup>th</sup> ed., pp. 172-178, 949-982.
- N. Ake Johnson, 1972, "Chemical Structure and Teratogenic Properties," *Acta Pharm.*, pp. 521-542.
- Hideshima et al., 2000, "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy," *Blood* 96(9):2943-2950.
- Goerner et al., 2002, "Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias," *Biology of Blood and Marrow Transplantation* (Abstract only) 8(1):47-56, accessed from Database STN/CAPLUS, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, Accession No. 2002:1195127.
- Kurzrock, 2002, "Myelodysplastic syndrom overview," *Seminars in Hematology* (Abstract only) (Suppl. 2) 39(3).
- Bellamy et al., 2001, "Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes," *Blood* 97:1427-1434.
- Bennett et al., 1982, "Proposals for the classification of the myelodysplastic syndromes," *Br. J. Haematol.* 51:189-199.
- Bumm et al., 2003, "Emergences of clonal cytogenetic abnormalities in pH- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority," *Blood* 101:1941-1949.
- Cancer Therapy Evaluation Program, 1998, "Common toxicity criteria," Version 2.0, Bethesda, MD: Division of Cancer Treatment and Diagnosis, National Institutes of Health, Mar. 1998. (Accessed Jan. 18, 2005, at <http://ctep.cancer.gov/reporting/ctc.html>).
- Cheson et al., 2000, "Report of an international working group to standardize response criteria for myelodysplastic syndromes," *Blood* 96:3671-3674.
- Claessens et al., 2002, "In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis," *Blood* 99:1594-1601.
- Corral et al., 1999, "Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF- $\alpha$ ," *J. Immunol.* 163:380-386.
- Davies et al., 2001, "Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma," *Blood* 98:210-216.
- Deeg et al., 2002, "Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study," *Leukemia* 16:162-164.
- Gersuk et al., 1996, "Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome," *Blood* 88(3):1122-1123.
- Goldberg et al., 2003, "Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy," *Blood* 101:781.
- He, W., et al., 1993, Abstract of papers, 206th American Chemical Society, Chicago, IL; Med. Chem., paper 216.
- Hellstrom-Lindberg et al., 1997, "Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model," *Br. J. Haematol.* 99:344-351.
- Jaffe et al., eds., 2001, "World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues," Lyon, France: IARC Press pp. 61-74.
- Kaplan et al., 1958, "Nonparametric estimation from incomplete observations," *J. Am. Stat. Assoc.* 53:457-481.
- Kitagawa et al., 1997, "Overexpression of tumor necrosis factor (TNF)- $\alpha$  and interferon (INF)- $\gamma$  by bone marrow cells from patients with myelodysplastic syndromes," *Leukemia* 11:2049-2054.
- List et al., 2005, "Efficacy of Lenalidomide in myelodysplastic syndromes," *N. Engl. J. Med.* 352(6):549-557.
- List et al., 2004, "Myelodysplastic syndromes," *Wintrobe's Clinical Hematology*, 11<sup>th</sup> ed., Philadelphia: Lippincott Williams & Wilkins pp. 2207-2234.
- List et al., 2004, "Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells," *Exp. Hematol.* 32:526-535.
- Maciejewski et al., 2002, "A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome," *Br. J. Haematol.* 117:119.
- Moreira et al., 1993, "Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation," *J. Exp. Med.* 177:1675-1680.
- Peddie et al., 1997, "Oxidative DNA damage in CD34+ myelodysplastic cells in associated with intracellular redox changes and elevated plasma tumor necrosis factor- $\alpha$  concentration," *Br. J. Haematol.* 99:625-631.
- Rajapaksa et al., 1996, "Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells," *Blood* 88:4275-4287.
- Raza et al., 1995, "Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes," *Blood* 86:268-276.
- Richardson et al., 2002, "Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma," *Blood* 100:3063-3067.
- Rose et al., 1995, "The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS)," *Br. J. Haematol.* 89:831-837.
- Tauro et al., 2002, "Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes," *Leukemia* 16:785-790.
- Turk et al., 1996, "Binding of thalidomide to alpha 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production," *PNAS USA* 93:7552-7556.
- Baker AF, Bellamy WT, Glinsmann-Gibson B, Heaton R, Buresh A, Grogan TM, List AF, Biological response to thalidomide in remitting patients with myelodysplastic syndrome (MDS): Evidence for induction of neoplastic vascular endothelial growth factor (VEGF) resistance. *Blood* 2001; 98(11): 353a-4a, Abstract # 1490.
- Bours V, Franzoso G, Brown K, Park S, Azarenko V, Tomita-Yamaguchi M, Kelly K, Siebenlist U. Lymphocyte activation and the family of NF- $\kappa$ B transcription factor complexes. *Current Topics in Microbiology and Immunology* 1992; 182: 411-20.
- List, AF, Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes, *Forum Trends in Experimental and Clinical Medicine*, 9: 35-45, 1999.
- List, AF, Brasfield, F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R., Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. *Blood* 1997; 90(9): 3364-9.
- List, AF, New approaches to the treatment of myelodysplasia, *The Oncologist* 2002; 7 Suppl. 1:39-49.
- Thomas, D.A., Aguayo, A., Estey, E., Albitar, M., O'Brien, S., Giles, F.J., Beran, M., Cortes, J., Zeldis, J., Keating, M.J., Barlogie, B., Kantarjian, H.M., Thalidomide as anti-angiogenesis therapy (rx) in refractory or relapsed leukemia. Abstract #2269, American Society of Hematology, Dec. 3-7, 1999.
- Raza, A., Lisak, L., Andrews, C., Little, L., Muzammil, M., Alvi, S., Mazzoran, L., Zorat, F., Akber, A., Ekabl, M., Razvi, S., Venugopal, P., Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS). Abstract #2935, Amer. Soc. of Hematology, Dec. 3-7, 1999.
- Raza, A., Lisak, L., Andrews, C., Little, L., Zorat, F., Shetty, V., Alvi, S., Mundle, S., Allampallam, K., Duran, M., Ekbal, M., Muzammil, M., Encouraging improvement in cytopenias of patients

- with myelodysplastic syndromes (MDS) with thalidomide. Abstract #111, Amer. Soc. of Clinical Oncology, May 20-23, 2000.
- Raza, A., Lisak, L., Little, L., Dean, L., Gezer, S., Venugopal, V., Summary and future anti-tumor necrosis factor (TNF) therapies in myelodysplastic syndromes (MDS). Abstract #2700, American Society Hematology, May 12-17, 2001.
- Mundle, S., Zorat, F., Shetty, V., Allampallam, K., Alvi, S., Lisak, L., Little, L., Dean, L., Nascimben, F., Ekbal, M., Durandt, M., Broderick, E., Venugopal, P., Raza, A., Thalidomide in myelodysplasia. Abstract #626, American Society of Hematology, Dec. 1-5, 2000.
- Raza, A., Lisak, L., Little, L., Ekbal, M., Durandt, M., Ali, E., Nascimben, F., Tareen, M., Venugopal, P., Thalidomide as a single agent of in combination with topotecan, pentoxifylline and/or enbrel in myelodysplastic syndromes (MDS). Abstract #627, American Society of Hematology, Dec. 1-5, 2000.
- Estey, E., Albitar, M., Cortes, J., Giles, F., Thomas, D., Koller, C., Beran, M., Kantarjian, H., Addition of thalidomide(T) to chemotherapy didn't increase remission rate in poor prognosis AML/MDS. Abstract #1394, American Society of Hematology, Dec. 1-5, 2000.
- Alvi, S., Henderson, B., Shaher, A., Dangerfield, B., Broderick, E., Jafri, N., Tareen, M., Durandt, M., Galili, N., Borok, R.Z., Raza, A., Determination of clonality in stromal and parenchymal cells pre and post thalidomide treatment in myelodysplasia. Abstract #1536, American Society of Hematology, Dec. 1-5, 2000.
- Alvi, S., Shaher, A., Henderson, B., Dar, S., Zorat, F., Broderick E., Lisak, L., Durandt, M., Reddy, P., Mundle, S., Galili, N., Borok, R.Z., Raza, A., Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. Abstract #1547, American Society of Hematology, Dec. 1-5, 2000.
- Dourado, C. MC., Seixas-Silva Jr., J.A., Besa, E.C., Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. Abstract #4855, American Society of Hematology, Dec. 1-5, 2000.
- Lisak, L.A., Little, L., Dean, L., Ekbal, M., Durandt, M., Hussain, M., Kaistha, V., Raza, A., Delayed responses to thalidomide in patients with myelodysplastic syndromes. Abstract #4861, American Society of Hematology, Dec. 1-5, 2000.
- Anders, O., Plath, F., Emmrich, J., Freund, M., Complete remission of therapy-resistant angiodysplasia of the stomach in myelodysplastic syndrome following thalidomide. Abstract #3820, American Society of Hematology, Dec. 7-11, 2001.
- Alvi, S., Shaher, A., Shikh, M., Anthwal, S., Siddiqi, F., Akhtar, A., Ashraf, H., Meager, R., Mundle, S., Shetty, V., Goldberg, C., Galili, N., Borok, R.Z., Raza, A., MDS patients with hematological response to thalidomide show enhanced in vitro growth potential. Abstract #1482, American Society of Hematology, Dec. 7-11, 2001.
- Alvi, S., Shaikh, M., Anthwal, S., Shaher, A., Tamosveiciene, D., Novick, A., Reddy, P., Allampallam, K., Hsu, W.T., Galili, N., Borok, R.Z., Raza, A., Cytogenetic and clonal profile of myelodysplastic syndromes (MDS) patients treated with thalidomide. Abstract #1483, American Society of Hematology, Dec. 7-11, 2001.
- Alvi, S., Anthwal, S., Shaikh, M., Shaher, A., Shetty, V., Mundle, S., Reddy P., Allampallam, K., BI, S., Zorat, F., Tamosveiciene, D., Rasila, K., Meagher, R., Westbrook, C., Galili, N., Gezer, S., Venugopal, P., Borok, R.Z., Raza, A., Thalidomide significantly augments proliferation and cytokine secretion to bone marrow cultures established from myelodysplastic syndrome (MDS) patients. Abstract #1484, American Society of Hematology, Dec. 7-11, 2001.
- Baker, A.F., Bellamy, W.T., Glinsmann-Gibson, B.I., Heaton, R., Buresh, A., Grogan, T.M., List, A.F., Biological response to thalidomide in remitting patients with myelodysplastic syndrome (MDS): Evidence for induction of neoplastic vascular endothelial growth factor (VEGF) resistance. Abstract #1490, American Society of Hematology, Dec. 7-11, 2001.
- Musto, P., Falcone, A., Bodenizza, C., Sanpaolo, G., Matera, R., Bisceglia, M., Carella, A.M., Thalidomide (THAL) significantly improves anemia in selected transfusion-dependent patients with myelodysplastic syndromes (MDS): relationship to serum and marrow levels of angiogenetic growth factors (AGF). Abstract #2606, American Society of Hematology, Dec. 7-11, 2001.
- Fabbri, A., Biscardi, M., Innocenti, F., Balestri, G., Gavazzi, S., Bellesi, G., Grossi, A., Thalidomide in combination with Amifostine in the treatment of MDS: evaluation of clinical and laboratory findings. Abstract #4819, American Society of Hematology, Dec. 7-11, 2001.
- Raza, A., Lisak, L., Dutt, D., Dean, L., Fantroy, L., Ali, E., Gezer, S., Hsu, W-T., Goldberg, C., Loew, J., Venugopal, P., Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS). Abstract #4830, American Society of Hematology, Dec. 7-11, 2001.
- Raza, A., Dutt, D., Lisak, L., Dean, L., Fantroy, L., Gezer, S., Ali, E., Goldberg, C., Loew, J., Hsu, W-T., Venugopal, P., Combination of thalidomide and enbrel for the treatment of patients with myelodysplastic syndromes (MDS). Abstract #4831, American Society of Hematology, Dec. 7-11, 2001.
- Shetty, V., Allampallam, K., Hussaini, S., Townsend, W., Dutt, D., Mundle, S., Alvi, S., Reddy, P.L., Ashraf, H., Galili, N., Saberwal, G.S., Anthwal, S., Shaikh, M.W., Heidelberg, A., Lisak, L., Gezer, S., Venugopal, P., Raza, A., Effects of anti-cytokine agents on apoptosis, proliferation, monocyte/macrophage number, microvessel density and cytokines following two successive clinical trials in 57 patients with myelodysplastic syndromes (MDS). Abstract #4837, American Society of Hematology, Dec. 7-11, 2001.
- Barlogie, B., Desikan, R., Munshi, N., Siegel, D., Mehta, J., Singhal, S., Anaissie, E., Single Course D.T. Pace Anti-Angiochemotherapy Effects CR in Plasma Cell Leukemia and Fulminant Multiple Myeloma (MM). Abstract #4180, American Society of Hematology, Dec. 4-9, 1998.
- Hideshima, T., Chauhan, D., Shima, Y., Noopur, R., Davies, F.E., Tai, Y., Treon, S.P., Lin, B.K., Schlossman, R.L., Richardson, P.G., Gupta, D., Muller, G.W., Stirling, D.I., Anderson, K.C., Thalidomide (THAL) and its Analogs Overcome Drug Resistance of Human Multiple Myeloma (MM) Cells to Conventional Therapy. Abstract #1313, American Society of Hematology, Dec. 1-5, 2000.
- Payvandi, F., Wu, L., Gupta, D., Hideshima, T., Haley, M., Muller, G., Chen, R., Anderson, K.C., Stirling, D., Effects of a Thalidomide Analog on Binding Activity of Transcription Factors and Cell Cycle Progression of Multiple Myeloma Cell Lines. Abstract #2487, American Society of Hematology, Dec. 1-5, 2000.
- Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y., Lin, B.K., Podar, K., Chauhan, D., Treon, S.P., Gupta, D., Mitsiades, C., Mitsiades, N., Hayashi, T., Richardson, P.G., Schlossman, R.L., Muller, G.W., Stirling, D.I., Anderson, K.C., Thalidomide (THAL) and Immunomodulatory Derivatives (IMiDS) Augment Natural Killer (NK) Cell Cytotoxicity in Multiple Myeloma (MM). Abstract #3617, American Society of Hematology, Dec. 1-5, 2000.
- Hideshima, T., Chauhan, D., Castro, A., Hayashi, T., Mitsiades, C., Mitsiades, N., Akiyama, M., Richardson, P.G., Schlossman, R.L., Adams, J., Anderson, K.C., NF-KB as a Therapeutic Target in Multiple Myeloma (MM). Abstract #1581, American Society of Hematology, Dec. 7-11, 2001.
- Lentsch, S., Rogers, M., Leblanc, R., Birsner, A., Shah, J., Anderson K., D'Amato R., 3-Amino-Phthalimido-Glutarimide (S-3APG) Inhibits Angiogenesis and Growth in Drug Resistant Multiple Myeloma (MM) *in vivo*. Abstract #1976, American Society of Hematology, Dec. 7-11, 2001.
- Park, Y., Kim, S.A., Kim, C.J., Chung, J.H., Mechanism of the Effect of Thalidomide on Human Multiple Myeloma Cells. Abstract #2685, American Society of Clinical Oncology, May 12-17, 2001.
- Payvandi, F., Wu, L., Haley M., Gupta, D., Zhang, L., Schafer, P., Muller, G.W., Chen, R., Anderson, K.C., Stirling, D., Thalidomide Analogs IMiDS Inhibit Expression of Cyclooxygenase-2 in Multiple Myeloma Cell Line and LPS Stimulated PBMCs. Abstract #2689, American Society of Hematology, Dec. 7-11, 2001.



Mitsiades, N., Mitsiades, C., Poulaki, V., Akiyama, M., Tai, Y., Lin, B., Hayashi, T., Catley, L., Hideshima, T., Chauhan, D., Treon, S.P., Anderson, K.C., Apoptotic Signaling Induced By Immunomodulatory Thalidomide Analogs (Imids) in Human Multiple Myeloma Cells; Therapeutic Implications. Abstract #3224. American Society of Hematology, Dec. 7-11, 2001.

Richardson, P.G., Schlossman, R.L., Hideshima, T., Davies, F., Leblanc, R., Catley, L., Doss, D., Kelly, K.A., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J., Chauhan, D., Munshi, N., Weller, E., Zeldis, J., Anderson, K.C., A Phase I Study of Oral CC5013, an Immunomodulatory Thalidomide

(THAL) Derivative, in Patients with Relapsed and Refractory Multiple Myeloma (MM). Abstract #3225. American Society of Hematology, Dec. 7-11, 2001.

Zangari, M. Tricot, G., Zeldis, J., Eddlemon, P., Saghaififar, F., Barlogie, B., Results of Phase 1 Study of CC5013, for the Treatment of Multiple Myeloma (MM) Patients Who Replase After High Dose Chemotherapy (HDCT). Abstract #3226. American Society of Hematology, Dec. 7-11, 2001.

\* cited by examiner

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.